Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports

Analyst Reports
May 16th 2025

Maxim - Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

May 15th 2025

Baird - New IST Data for Triple Combo Further Supportive of Potential in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 15th 2025

CLSA - Insightful readout; Strong TPS-below-50% result highlights Keytruda expansion opportunity; Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 15th 2025

Wilsons - INSIGHT-003 | Even in the arctic tumours; Maintain Overweight, A$1.05 PT(Analysts: Dr Shane Storey and Dr Lisa Worley)

May 15th 2025

Canaccord Genuity - Efti-nately worth another look; BUY, A$0.98 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 6th 2025

Bell Potter - Strong Survival Data Supports Path Forward in Head & Neck; Buy (spec.), A$0.70/sh (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 6th 2025

Wilsons - 17.6m OS in PD-L1 negative mHNSCC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

May 5th 2025

Baird - Encouraging Mature OS Data for Efti+Pembro in 1L HNSCC TPS<1; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 5th 2025

Maxim - Positive Median Overall Survival Data for Efti + Keytruda in 1L H&N Cancer - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

May 5th 2025

Canaccord Genuity - Positive HNSCC data is a good immu-step forward; BUY, Raising PT A$0.98 (from A$0.95) (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 5th 2025

CLSA - Head & neck OS data; Retain Buy, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 5th 2025

Jefferies - Phase 2B 1L HNSCC Update – mOS Impressive; BUY, PT A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

May 5th 2025

Canaccord Genuity - Head and neck CPS<1 efti-cacy success; BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 2nd 2025

Canaccord Genuity - The latest updates in IO; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 29th 2025

Baird - Phase 3 1L NSCLC Enrollment Ongoing; Broad Development Continues; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

March 25th 2025

Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

March 25th 2025

Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

March 4th 2025

Canaccord Genuity - 1H25 model update: All eyes on next HNSCC update; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

March 3rd 2025

Baird - Transferring Coverage: Compelling Opportunity for Efti in Phase 3 NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

February 26th 2025

Jefferies - 1HFY25: Did It Again; Buy, Raise PT to A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

January 24th 2025

Canaccord Genuity - TACTI-003 Cohort B musings, anticipated upcoming news flow; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

December 17th 2024

Jefferies - MRK drops anti-TIGIT in 1L mNSCLC, efti more important; Buy, A$2.00 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

December 16th 2024

Wilsons - Preparedness for approval in 1L mHNSCC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

December 12th 2024

Maxim - Positive Updated Data for Efti + Keytruda in 1L H&N Cancer - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

December 12th 2024

Jefferies - Phase 2B 1L HNSCC update – mOS continues to impress; Buy, A$2 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

December 12th 2024

Wilsons - TACTI-003-B | Approvable in HNSCC? Maintain Overweight, PT under review (Analyst: Dr Shane Storey)

December 12th 2024

Canaccord Genuity - Additional TACTI-003 Part B data impresses; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

December 9th 2024

Jefferies - To Initiate TACTI-004 Phase 3 Trial in 1L NSCLC; Rated Buy, Raise PT to A$2 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

November 14th 2024

Baird - INSIGHT-003 Data Adds Support for Efti in NSCLC Ahead of Phase 3; Rated OP, US$7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

November 14th 2024

Maxim - Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

November 14th 2024

CLSA - Checking-off key points; Positive survival data in triple combo incrementally derisk TACTI-004; Maintain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

November 14th 2024

Bell Potter - Lung cancer Phase 1 trial: Strong data update; Maintain Buy, A$0.70 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

November 14th 2024

Wilsons - INSIGHT-003 | Flexing in 1L NSCLC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

October 21st 2024

Maxim - P1 Study of IMP761 Moves to Dose Escalation Portion of Trial; Watching for Updates Around Three Core Efti Programs; Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

September 25th 2024

Canaccord Genuity - Upcoming FDA ODAC meeting puts mounting pressure on Keytruda; Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

September 19th 2024

Capital One - Head and Neck Expert Call – Key Takeaways; Reiterate OW; US$8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 16th 2024

Canaccord Genuity - ESMO update: HNSCC update an incremental positive; Rated Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

September 16th 2024

Capital One - Incremental Update on Cohort A (TACTI-003) at ESMO; KOL Call Tomorrow; Rated OW; US$8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 16th 2024

Bell Potter - No Major Revelations from ESMO Data; Maintain Buy, A$0.70 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

September 15th 2024

Baird - Update on Efti in HNSCC at ESMO; We Continue to View NSCLC as Top Setting; Maintain OP, US$6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

September 15th 2024

Wilsons - ESMO updates; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 15th 2024

CLSA - ESMO 2024-HNSCC presentation highlights favourable trends in efti + Keytruda; Rated Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

September 11th 2024

Capital One - Exciting HARMONi-2 Data at WCLC Shouldn’t Discount Efti/Pembro Combo in NSCLC; Reiterate OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 11th 2024

CLSA - Head & neck take two: Hopeful on durability data at ESMO, may support positive outlook; Retain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

September 9th 2024

Wilsons - Summit data relevance limited; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 3rd 2024

Capital One - IMMP Reports FY24: ESMO Update on TACTI-003 (HNSCC, CPS>1) on 9/15; Rated OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

August 30th 2024

Jefferies - FY24: Adventure of a Lifetime; Buy, A$1.10 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

August 23rd 2024

Bell Potter - Looking out for two LAG-3 ESMO Presentations; Maintain Buy, A$0.75 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

August 16th 2024

Canaccord Genuity - IMM highlights efti's unique mechanism and upcoming news flow at CG Growth Conference; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

August 1st 2024

Ladenburg Thalmann - Moving Forward and Onward; Reaffirm Buy, US$8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

July 25th 2024

Wilsons - Next steps for Efti in HNSCC; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

July 16th 2024

Capital One - IMMP: Takeaways from our KOL Call on TACTI-003; Rated OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

July 15th 2024

Bell Potter - TACTI-003 Cohort B Update; Maintain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

July 12th 2024

Canaccord Genuity - Efti continues to impress in CPS<1 HNSCC patients; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

July 12th 2024

Maxim - Positive Response Data for Efti + Keytruda in 1L H&N Cancer, Cohort B; Reiterate Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

July 12th 2024

Ladenburg Thalmann - Efti is Making Keytruda Work in PD-L1 Negative Patients in Head and Cancer; Rated Buy, US$8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

July 12th 2024

CLSA - Heating up; Positive head & neck PD-1 negative readout highlights opportunity; Maintain BUY, A$0.95 PT and O-PF rating retained (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

July 11th 2024

Baird - Efti in Combo With Keytruda Shows Encouraging 35% ORR in 1L HNSCC; Maintain OP, US$6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

July 11th 2024

Jefferies - Phase 2B 1L HNSCC update – ORR in CPS <1 improves c9%; Buy, A$0.93 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

June 28th 2024

Bell Potter - Combo data supportive in HNSCC; Retain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

June 28th 2024

Canaccord Genuity - Headstrong conviction in Efti's potential clinical impact; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

June 28th 2024

Wilsons - TACTI-003 download: take a pause; Maintain Overweight, A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 27th 2024

Maxim - An Imbalance in the 1L H&N Control Arm Data but the Overall Efti + Keytruda Combo is Positive and Consistent; Reiterate Buy, $12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

June 27th 2024

Ladenburg Thalmann - Our Thoughts on TACTI-003 Data; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

June 27th 2024

Capital One - IMMP: Cohort Imbalance Muddies Cohort A Topline Data, But Could Still Improve; Rated OW; $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

June 27th 2024

CLSA - TACTI-003: Cohort A data; Cohort A delivers a ‘pass’ mark, but patient imbalances cloud comparison; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

June 27th 2024

Baird - Efti Shows Favorable Trend on ORR in Phase 2b Trial in HNSCC; Maintain OP, $6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

June 27th 2024

Wilsons - Immutep Limited (IMM) | TACTI-003: the real results; Maintain Overweight, A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 17th 2024

Capital One - IMMP: TACTI-004 Design Unveiled; Investor Focus Is on 1L HNSCC Data; Rated OW; $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

June 12th 2024

Maxim - Is Efti the Answer for Merck's Keytruda Franchise? Going to P3 in 1L Lung is a Big Deal; Maintain Buy, Raise PT to $12 (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

June 6th 2024

Baird - Collab with Merck Provides Downside Support Ahead of Phase 2 HNSCC Data; Maintain OP, $7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

June 5th 2024

CLSA - Cap raise strengthens position; A$100m raise reduces sentiment risk ahead of key readout; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 17th 2024

Capital One - IMMP: No LAG(gard) Here, Efti’s Ready to Go Pivotal; Initiating at OW, $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

May 16th 2024

CLSA - Higher dosing showing promise; MBC efti+chemo dose escalation complete response, no safety concerns; Rated BUY, A$0.95 (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 15th 2024

Canaccord Genuity - Efti poster at ESMO: Continued safety is a win; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 3rd 2024

Bell Potter - More Great Data, Major Catalyst Nears; Maintain Buy, A$0.80 Valuation (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 2nd 2024

Canaccord Genuity - Ticking all the boxes - initial positive read from efti in soft tissue sarcoma; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 30th 2024

Ladenburg Thalmann - 3Q FY2024: Bullish on Randomized Trial Readout; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 29th 2024

Canaccord Genuity - Not LAG-ing Behind in the Immune Oncology Race; Initiating Coverage with a BUY Rating and A$1 tgt (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 24th 2024

Ladenburg Thalmann - TACTI-003 Interim Readout: Boosting Confidence in Head and Neck; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 24th 2024

Maxim Group - Preliminary Data from TACTI-003 Outperforms Historical Control by 5x; Full ORR Data Expected Within C2Q24; Mtn Buy, $10 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

April 24th 2024

Baird - Encouraged by Efti Topline Results in PD-L1 Negative Head and Neck Cancer; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

April 24th 2024

CLSA - 1L Head & Neck Cohort B ORR 5x higher vs Keytruda monotherapy; Response rate encouraging in difficult to treat patients, surprises to the upside (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

April 24th 2024

Jefferies - efti/pembro 5x ORR increase over pembro monoRx (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

April 24th 2024

Bell Potter - Exceptional first taste of TACTI-003 data, 27% ORR ~5x higher than historical ORR of ~5%; Maintain Buy and increase Price Target to A$0.80 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

April 24th 2024

Wilsons - Efti boosts Keytruda response 5x; Maintain Overweight, A$1.04 tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 19th 2024

Ladenburg Thalmann - Autoimmune Program is Advancing into Clinic; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 18th 2024

Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 4th 2024

Bell Potter - Thoughts Ahead of TACTI-003 Readout; Maintain Buy, A$0.65 tgt (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

March 27th 2024

CLSA - Checking in; Maintain Buy, A$0.95 tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 6th 2024

Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

March 6th 2024

Baird - First Data on Highest Dose Ever of Efti Includes a Complete Response; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

March 5th 2024

Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 5th 2024

CLSA - Nearing the Checkpoint; Upcoming HNSCC trial readout & Ph3 NSCLC progress key focus in CY24; Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 4th 2024

Bell Potter - Multiple Indications Advancing; Maintain Buy, Raise tgt to A$0.65 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

February 29th 2024

Ladenburg Thalmann - Eyes Are on Controlled Study (TACTI-003) Results; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

February 26th 2024

goetzpartners securities - Efti MoA strong durable in multiple cancers; Reit Buy, A$2.74 tgt (Analyst: Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

December 11th 2023

CLSA - Big empty; Merck’s weak TIGIT Ph2 update in contrast to LAG-3’s promising outlook; Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

December 7th 2023

Bell Potter - Analyst Outlook & Top Stock Picks December 2023

https://www.linkedin.com/posts/immutep-ltd_bell-potter-analyst-outlook-stock-picks-activity-7141211179351195648-GKqM?utm_source=share&utm_medium=member_desktop

For a copy of this research report please contact your Bell Potter advisor

November 1st 2023

Baird - F1Q24: Encouraged by Efti Data in 1L NSCLC and Beyond; Reit Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

November 1st 2023

Ladenburg Thalmann - Impressive in Lung Cancer, Next is Head and Neck, This Time Placebo-Controlled; Rated Buy, $8.30 PT

For a copy of this research report please contact your Ladenburg Thalmann advisor

October 30th 2023

goetzpartners securities - Changing the game in lung cancer survival; Reit Buy, A$2.88 tgt (Analyst: Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 24th 2023

Baird - More Mature OS Data at ESMO Provide Further Support for Efti in 1L NSCLC; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

October 24th 2023

Bell Potter - Staggering Survival Data in NSCLC; Maintain Buy, A$0.55 Tgt (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

October 23rd 2023

Maxim Group - Positive Survival Data for Efti + Keytruda in 1L Lung Cancer at ESMO; Sets Stage for P3 Study in CY24; Mtn Buy, $10 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

October 23rd 2023

Ladenburg Thalmann - ESMO: Data Better Than Expected; Reiterate Buy and $8.30 PT

For a copy of this research report please contact your Ladenburg Thalmann advisor

October 23rd 2023

CLSA - Good start ahead of key trial. Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

October 23rd 2023

Jefferies - Median 35.5 month OS in 1L metastatic NSCLC. Rated Buy, A$1 tgt (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

October 23rd 2023

Wilsons - Just double it! Survival that is; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

October 17th 2023

Baird - Efti Continues to Look More Promising than Anti-Tigit in ESMO Abstract; Rated OP, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

October 17th 2023

Wilsons Equity Research - NSCLC benefit stuns in PD-L1 ≥50%; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 13th 2023

goetzpartners securities - Fully exploiting LAG3 oncology game changer. Reit Buy, A$2.88 tgt (Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 10th 2023

CLSA - FY24 a pivotal year with key readouts ahead and cash runway to CY26. Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

August 31st 2023

Jefferies - FY23: I Say A Little Prayer; Mtn Buy and A$1 tgt (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

August 28th 2023

Baird - Efti Continues to Look More Promising than Anti-TIGIT; $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

August 2nd 2023

Baird - Unique LAG-3 Agent with Fast Track Designation; Initiate OP, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

July 3rd 2023

Bell Potter - Cash Secured. Readouts 2H CY2023. (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

June 13th 2023

Wilsons Equity Research - Funding secured; bring on the readouts; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 29th 2023

goetzpartners securities - Efti-combo's boost efficacy of lung cancer standard of care; Reit Buy, A$2.88 tgt

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 29th 2023

Petra Capital - 2L HNSCC detailed results: Wait for ASCO; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 26th 2023

Wilsons Equity Research - Final 2L HNSCC data: still doubling ORR; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 25th 2023

Petra Capital - Triple combo data in NSCLC shows promise; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 24th 2023

Bell Potter - Efti's Efficacy - Strong Rationale for Prioritising NSCLC (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 18th 2023

Petra Capital - First OS look in NSCLC impresses; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 17th 2023

Maxim Group: Efti+Keytruda Leads to Positive Survival Data in 1L Lung Cancer; Raise tgt to $10, mtn Buy (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

May 17th 2023

Wilsons Equity Research - No longer a need to weigh up chemo; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 17th 2023

CLSA - Efti & Keytruda’s excellent adventure; OS data shows meaningful benefit in NSCLC, without need for chemo (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

May 3rd 2023

Wilsons Equity Research - Still a compelling opportunity; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 28th 2023

Petra Capital - Immutep Ltd (IMM) - 3QFY23 – Clinical Progress on all fronts; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

April 19th 2023

Maxim Group - New Efti Trial Announced in Sarcoma; Moving into Neoadjuvant Setting; Buy, $8 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

April 5th 2023

Petra Capital - Immutep Ltd (IMM) - Efti activity in PD-1 refractory patients re-confirmed; Reit Buy, A$1.28 Tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

April 4th 2023

goetzpartners securities - Potential standard of care in lung and other cancers; Reit Buy, Up Tgt to A$2.88

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 3rd 2023

Ladenburg Thalmann - Final 2L Lung Data Looks Fine; the Focus Is on 1L NSCLC; Reit Buy, $8.30 Tgt (Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

April 3rd 2023

Wilsons Equity Research - Efti to enable expansion of Keytruda’s TAM; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 14th 2023

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing & OS Primary in Breast Cancer; Buy, $8 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

March 8th 2023

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

February 28th 2023

Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

February 10th 2023

Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

January 31st 2023

Ladenburg Thalmann - One Asset and Multiple Opportunities; Reit Buy and $8.30 Target (Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

December 14th 2022

Bell Potter - Analyst Outlook & Stock Picks for 2023

For a copy of this research report please contact your Bell Potter advisor

December 7th 2022

Wilsons - Healthcare in 2023: Our Top Six

December 6th 2022

Bell Potter - Immutep (IMM): Manufacturing process established for IMP761 (autoimmune disease targeting antibody) (Analyst: Dr Tara Speranza)

December 5th 2022

Jefferies - Immutep (IMM AU, BUY): Expanding into Urothelial Cancer (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

November 29th 2022

CLSA Equity Research - Immutep (IMM) announces a new collaboration with Merck KGaA and Pfizer for a Ph 1 clinical trials for metastatic urothelial cancer (INSIGHT-005) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

November 29th 2022

Petra Capital - Immutep Limited (IMM) - New clinical trial collaboration with Merck KGaA/Pfizer for Phase 1 with efti in urothelial cancer, a positive with more to come (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

November 29th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Keytruda isn’t the only kid in the Efti sandbox (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 16th 2022

Petra Capital - Immutep Limited (IMM) - Stellar NSCLC showing at SITC, registrational trial in 2H23 (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

November 13th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): Efti lung benefits better longer versus standard of care

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 11th 2022

Ladenburg Thalmann - SITC: Efti Is Active in NSCLC, Adaptive Registration Trial Is Next; Reaffirm Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

November 11th 2022

CLSA Equity Research - Unrealised value - Lung data update supportive of overall value realisation into CY23 (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

November 11th 2022

Wilsons Equity Research - Immutep Limited (IMM) | A registrational trial within 12 months! (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 10th 2022

Jefferies - IMM AU Releases Positive SITC Data (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

November 10th 2022

Maxim Group - Efti in 1L Lung Cancer at SITC – Response Rates are Favorable, but it's the Duration of Response that Impresses (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

November 8th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Durable responses in 1L NSCLC with Efti (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 7th 2022

Maxim Group - Late-Breaking Abstract for Eftilagimod Selected for SITC Press Conference (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

October 26th 2022

Ladenburg Thalmann - NSCLC Is the Focus for Late-stage Development; Reiterate Buy and $8.30 PT (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

October 25th 2022

Petra Capital - Immutep Limited (IMM) - TACTIcal IO Positioning - Hard to Ignore; Initiating with Buy rating and A$1.19 Target (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor.

October 9th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): FDA fast-tracks efti as chemo alternative in NSCLC

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 6th 2022

CLSA Equity Research - PD-L1 competition good for efti - GSK’s PD-L1 result highlights increasing competition for Keytruda (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

October 5th 2022

Maxim Group - Looking Towards SITC In November; Eftilagimod Abstracts Accepted (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

October 4th 2022

CLSA Equity Research - Tracking positively - FDA NSCLC Fast Track designation follows promising data readout (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

October 4th 2022

Wilsons Equity Research - Immutep Limited (IMM) | FastTrack for Efti in 1st line NSCLC (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 15th 2022

goetzpartners securities Research - Immutep Limited (IMM-AU): Boosting checkpoint utility in lung and other solid cancers

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 5th 2022

CLSA Equity Research - Immutep : On to the main acts (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

August 31st 2022

CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

August 31st 2022

Jefferies - Immutep Ltd | BUY : IMM AU | AUD0.29 | PT: AUD1.00 (AUD0.90) | % to PT: +245% - FY22: Run (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor

August 2nd 2022

Maxim Group - Interim Data from TACTI-002 Study to be Presented at World Conference on Lung Cancer, Aug 6-9 (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

August 1st 2022

Wilsons Equity Research - Chemo-free efficacy – yes please! (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

August 1st 2022

Ladenburg Thalmann - One Drug, Multiple Late-stage Opportunities; Reiterate Buy Rating (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

July 22nd 2022

Jefferies - IMM AU - Increased Importance of TACTI-003 for MRK in HNSCC (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

June 29th 2022

goetzpartners securities Research - Efti-PD-X synergy opens >$6bn NSCLC opportunity

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 7th 2022

CLSA Equity Research - Not Lag-ging - Ph2 data support progression to Ph3 on positive results (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

June 7th 2022

Bell Potter - IMM - a very viable big pharma target (Analyst: Dr Tara Speranza)

For a copy of this research report please contact your Bell Potter advisor

June 6th 2022

Maxim Group - Positive 1L Lung Cancer Data for Efti/Pembro at ASCO; Webcast Today at 6pm ET (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

June 6th 2022

Wilsons Equity Research - ASCO data lays the path to Phase III (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 4th 2022

Jefferies - IMM AU releases ASCO Data (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

May 27th 2022

CLSA Equity Research - Another promising readout - 1L NSCLC readout shows slight increase in ORR in larger patient cohort (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

May 27th 2022

Wilsons Equity Research - Immutep Limited (IMM) | Efti continues to win in NSCLC (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 12th 2022

Maxim Group - Disappointing Data for TIGIT; Nice Set up for Immutep’s soluble LAG-3 in 1L NSCLC? ASCO is Next (Analyst: Dr Naureen Quibria)

For a copy of this analyst report please contact your Maxim advisor John Law - jlaw@maximgrp.com or biotech analyst Naureen Quibria - nquibria@maximgrp.com

May 5th 2022

CLSA Equity Research - Raising the profile - AIPAC data continues to support MOA ahead of key conference (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

May 5th 2022

Bell Potter - Breast cancer trial data supports mechanism of action (Analyst: Dr Tara Speranza)

For a copy of this research report please contact your Bell Potter advisor

April 29th 2022

Wilsons Equity Research - Immutep Limited (IMM) | A coveted ASCO spot for Efti (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 25th 2022

Ladenburg Thalmann - ELCC Abstract: First Data in 2L NSCLC from TACTI-002; Reiterate Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

March 24th 2022

Jefferies - New TACTI-002 Data - Efficacy in Line, SE Lower (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

March 24th 2022

Wilsons Equity Research - Immutep Limited (IMM) | IO non-responder patients saved by Efti (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 24th 2022

CLSA Equity Research - Keep on keeping on - 2L NSCLC within expectations, but 1L HNSCC & NSCLC remain focus (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

March 21st 2022

Ladenburg Thalmann - The Key Approval Arrived in the LAG-3 Arena (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

March 20th 2022

CLSA Equity Research - LAG-3 launch pad - FDA approval of LAG-3 therapy a key milestone for the sector (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

March 19th 2022

Jefferies - First LAG-3 Checkpoint Inhibitor Approved (ASX: IMM) (Analyst: Dr David Stanton)

For a copy of this analyst report please contact your Jefferies advisor.

March 1st 2022

CLSA Equity Research - Hitchin’ a ride - BMS’ LAG-3 FDA approval could see increased interest in I-O sector (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

February 23rd 2022

Maxim Group - Reports Half-Year Results; Eyeing the First External LAG-3 Approval from Bristol (Analyst: Dr Naureen Quibria)

For a copy of this Analyst report please contact your Maxim advisor John Law - jlaw@maximgrp.com or biotech analyst Naureen Quibria - nquibria@maximgrp.com

February 4th 2022

Alliance Global Partners - Indications Come and Go, But Immutep's Development of Efti Is About LAG-3 Itself

January 31st 2022

Ladenburg Thalmann - Our Top Picks for 2022 (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

Ladenburg has selected Immutep as one of its top 3 biotech stock picks for 2022. For a copy of this research report please contact your Ladenburg advisor.

December 14th 2021

Wilsons Conviction Insights Report - December 2021 - Immutep is a top biotech pick (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

December 7th 2021

Wilsons Equity Research - Healthcare in 2022: The Top Six (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

Wilsons has included Immutep as one of its top six healthcare stocks for 2022.

December 1st 2021

Jefferies - Turning Cold Cancers Hot – Initiating at Buy - TP to $A1 (ASX: IMM) (Analyst: Dr Dave Stanton)

For a copy of this Analyst report please contact your Jefferies advisor.

November 23rd 2021

Taylor Collison - AIPAC disappoints but TACTI-003 adding value - Increasing TP to $A1.36 (from $A1.19) (ASX: IMM) (Analyst: Dr Dennis Hulme)

For a copy of this Analyst report please contact your Taylor Collison advisor.

November 18th 2021

Wilsons Equity Research - Immutep Limited (IMM) | Efti impresses in HNSCC and aids the young & forgotten in metastatic breast cancer (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 17th 2021

Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pivotal in mBC

November 17th 2021

goetzpartners securities -Data highlights efti efficacy and potential central role in cancer therapy - Reiterate OUTPERFORM and TP of AUD 1.350

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 10th 2021

CLSA Equity Research - Not worth less today than yesterday - Increasing TP to A$1.33 (from A$1.19) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

November 10th 2021

Wilsons Equity Research - AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 4th 2021

Wilsons Equity Research - O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

October 16th 2021

CLSA Equity Research - On the right pathway - Initiating coverage with a Buy Rating of A$1.19 TP (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

October 13th 2021

Corporate Connect - A Truly Undervalued Company – Target Price of A$2.20 (ASX:IMM) (Analyst: Marc Sinatra)

September 21st 2021

Maxim Group - The Case for LAG-3 is Building

August 31st 2021

Maxim Group - Annual FY Update; AIPAC Final Data Approaching

August 3rd 2021

Ladenburg Thalmann - New Age Immune Regulator - Initiate with a Buy Rating of US$8.30 TP (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

July 16th 2021

Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 TP

July 14th 2021

Bell Potter - Creating Value with Phase 3 around the corner – Increasing TP to AUD 1.00 (from AUD 0.85)

For a copy of this research report please contact your Bell Potter advisor

July 7th 2021

goetzpartners securities -LAG-3 therapies taking immunology to the next level - Increasing TP to AUD 1.35 (from AUD 1.24)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

July 6th 2021

Taylor Collison - Efti development program expanded - Increasing TP to AUD 1.19 (from AUD 0.85)

For a copy of this research report please contact your Taylor Collison advisor.

June 10th 2021

Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 Immunotherapy — increasing to US$9 (from US$6)

June 5th 2021

goetzpartners securities - Efti combos move towards centre stage at ASCO : Increasing TP to A$1.24 (from A$0.90)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 5th 2021

Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares Remain Undervalued

May 20th 2021

goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 3rd 2021

Corporate Connect - Efti a highly sought after compound for mono & combo Cancer treatment

April 9th 2021

Bell Potter - Efti granted Fast Track - A vote of confidence (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

April 8th 2021

Alliance Global Partners - FDA's Fast Track for Efti Suggests Regulators Echo Large Pharma Enthusiasm Surrounding LAG-3 Immunotherapy

March 31st 2021

Bell Potter - Validation for LAG-3 arrives (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

March 25th 2021

goetzpartners securities - BMS Study Identifies LAG-3 - PD-1 as Potential 'Key Strategy'

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 25th 2021

Maxim Group - Bristol Brings LAG-3 to the Forefront in Checkpoints with First Positive P3 Trial; Bodes Well for Efti and LAG-3 Pipeline

March 16th 2021

Maxim Group - Success in 2L H&N Cancer Leads to Second Collaboration to Move into 1L – Reiterate Buy

March 16th 2021

goetzpartners securities - Targeting first-line head and neck with Merck & Co

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 6th 2021

Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 25th 2021

Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)

For a copy of this research report please contact your Bell Potter advisor.

February 5th 2021

Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

January 26th 2021

Alliance Global Partners - Raising PT to $6 from $5; MBC Program Thrown a Lifeline by OS Data as IMMP Shares Find Their Heading for the Year of the Sea Shanty

December 15th 2020

goetzpartners securities - Door re-opens to first eftilagimod alpha approval

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

December 11th 2020

Maxim - Efti Was Out in Breast Cancer...Or Was it? Update from Ongoing SABCS meeting, Raising PT to $8

November 19th 2020

Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete

November 11th 2020

Maxim - The Data for Efti in Lung and H&N Continues to Build – Raising PT to $4, from $2

November 11th 2020

goetzpartners securities - Striking support for efti - checkpoint inhibitor combos

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

November 4th 2020

Maxim - TACTI-002 Data (efti + pembro) to be Presented at SITC Meeting; Late Breaker Poster

October 27th 2020

Bell Potter - Efti now tackling COVID-19 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

September 23rd 2020

Alliance Global Partners - Eclipsing the LAG-3 Laggards in the Running for the Next Breakthrough in Immunotherapy

September 18th 2020

Taylor Collison - Immutep (IMM) Further positive efti data at ESMO

September 17th 2020

Bell Potter - Underappreciated immunotherapy player with leadership in LAG-3 (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

August 26th 2020

Taylor Collison - BMS/Dragonfly deal drives valuation upgrade

June 3rd 2020

goetzpartners securities - ASCO data underscores efti-PD-1 / L1 synergy

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

June 3rd 2020

Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)

For a copy of this research report please contact tnjain@bellpotter.com.au

June 2nd 2020

JonesTrading - Responses to Efti + Pembro are Deepening Over Time, as is the Combo’s Market Opportunity with ASCO Data Positing Promise in New Indications

May 14th 2020

goetzpartners securities - First in class opening the cancer immune throttle

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 30th 2020

Maxim - Data From TACTI-002 Continues to be Positive, Activity In the Space Bodes Well for Immutep

April 22nd 2020

Taylor Collison - Immutep (IMM) Leading not LAGging

March 27th 2020

Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

March 27th 2020

JonesTrading - AIPAC Setback Leaves a Mark on Efti’s Otherwise Impeccable Clinical Report Card, but Don’t Warrant a Failing Grade for Immutep

March 26th 2020

goetzpartners securities - Efti breast trial: Down certainly not out

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 24th 2020

JonesTrading - Efti + Pembro Value Proposition in NSCLC is Crystallizing as TACTI-002 Suggests Combo is Competitively Effective and Far More Tolerable

February 20th 2020

Maxim - Valuation is Rising as First of 2 Key Catalysts Delivers (TACTI-002 in Lung Cancer, H&N); Breast Cancer P2b is Next (CY1Q20)

February 20th 2020

goetzpartners securities - Efti-pembro combo: A new option in NSCLC?

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

February 18th 2020

Bell Potter - Global leader in LAG-3, the hottest emerging immune checkpoint (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

January 30th 2020

Maxim - Inflection Points Approaching- Lung Cancer Data (February), Breast Cancer Data (March)

January 11th 2020

Maxim - TACTI-002 Head & Neck Cancer Study is Expanding, Data Updates Over 2020 – Reiterate Buy